|
Company data displayed is for sample purposes only and may not reflect the most current information available on Emerging Markets Information Service (EMIS).
DAEBONG LS CO.,LTD.
Main Activities: Pharmaceutical and Medicine Manufacturing
 |
Please check the full coverage of information what EMIS can offer you. | SEE SAMPLE |
Company Information |
|
Full name DAEBONG LS CO.,LTD. Headquarters 122B-9L,NAMDONG IND. COM.,692-8, GOJAN-DONG, NAMDONG-GU, INCHEON; Incheon; Incheon; 405820 |
Status: Listed Legal Form: Public Limited Company Operational Status: Operational Financial Auditors: Ernst & Young (2011) Incorporation Date: July 22, 1987 Total Employees: 65 Tel: 032-817-8800-7 |
|
Company Description |
| The sales is going up with the increased demand o fthe medical and cosmetic raw material amid the increased production in the medical and comstic industries. It maintais a stable financial structure despite the a little down of the liquidity level amid the improved the cost ratio. It has succeeded in the getting the patent on the prodcution recipe of the Pioglitazon, a medicine for diabetes. The growth in the medical raw material is expected amid the production expansion by the pharmacy companies | ||
|
||
Company Analysis |
| According to the Individual - Audited financial statement for the first half of 2012, total net operating revenues increased with 7.68%, from KRW 18,273,693 thousands to KRW 19,677,704 thousands. Operating result decreased from KRW 1,625,992 thousands to KRW 1,190,233 thousands which means -26.80% change. The results of the period decreased -14.69% reaching KRW 1,228,614 thousands at the end of the period against KRW 1,440,193 thousands last year. Return on equity (Net income/Total equity) went from 4.21% to 3.43%, the Return On Asset (Net income / Total Asset) went from 3.72% to 2.98% and the Net Profit Margin (Net Income/Net Sales) went from 7.88% to 6.24% when compared to the same period of last year. The Debt to Equity Ratio (Total Liabilities/Equity) was 15.27% compared to 13.02% of last year. Finally, the Current Ratio (Current Assets/Current Liabilities) went from 7.80 to 6.36 when compared to the previous year. |
Key Executives |
|
|||||
|
|||||
|
|||||
|
|||||
|
|||||
Companies with Similar Main Activities |
FULL COMPANY PROFILE
|
|
2012 H1 (non-cons) |
2011 Y (non-cons) |
|
 | ||
| Audited | Audited | |
| ||
| KR listed company financials | KR listed company financials | |
| ||
| Unit | Thousands | Thousands |
| ||
Balance Sheet
| ||
Total Assets |
41,287,552 |
41,539,322 |
| ||
Current Assets |
27,272,294 |
27,682,468 |
| ||
Total Liabilities |
5,469,275 |
6,428,556 |
| ||
Shareholders Equity |
35,818,277 |
35,110,766 |
| ||
Current Liabilities |
4,288,936 |
5,192,341 |
| ||
| * All the accounts are in KRW. | ||
Income Statement
| ||
Total Operating Revenue |
19,677,704 |
37,278,932 |
| ||
Operational Profit (Loss) |
1,190,233 |
2,455,879 |
| ||
Net Profit (Loss) |
1,228,614 |
2,375,979 |
| ||
| * All the accounts are in KRW. | ||
Ratios
| Profitability Ratios | ||
| ||
Return on Assets (ROA) |
2.98% |
5.72% |
| ||
Return on Equity (ROE) |
3.43% |
6.77% |
| ||
Return on Sales (ROS) |
6.24% |
6.37% |
| ||
Return on Capital |
3.32% |
6.54% |
| ||
Gross Profit Margin |
16.19% |
16.23% |
| Efficiency Ratios | ||
| ||
Current asset turnover |
0.72x |
1.35x |
| ||
Asset Turnover |
0.48x |
0.90x |
| Valuation figures and ratios | ||
| ||
Earning Before Interests and Taxes (EBIT) |
1,065,274 |
1,956,546 |
| ||
EBITDA |
1,213,303 |
2,459,895 |
| ||
Bookvalue (BV) |
35,589,856 |
34,890,934 |
| Liquidity Ratios | ||
| ||
Current Ratio |
635.88% |
533.14% |
| ||
Quick ratio |
496.75% |
413.79% |
| ||
Doom's day ratio |
36.56% |
42.9% |
| ||
Cash Flow to Debt |
-12.07% |
1.87% |
| Leverage Ratios | ||
| ||
Leverage ratio |
115.27% |
118.31% |
| ||
Interest Coverage Ratio |
27,070.28% |
|
| ||
Debt to equity |
15.27% |
18.31% |
| ||
Debt to total assets |
13.25% |
15.48% |
| ||
Long Term Debt to Capital |
3.19% |
3.4% |
| Market ratios | ||
| ||
Price/Book Ratio |
0.82 |
0.86 |
| Trend Ratios | ||
| ||
Revenue Trend |
107.68% |
111.64% |
| ||
Net Income Trend |
85.31% |
72.65% |
| ||
 |